Compare CFND & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFND | VNRX |
|---|---|---|
| Founded | N/A | N/A |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.1M | 24.5M |
| IPO Year | 2025 | 2012 |
| Metric | CFND | VNRX |
|---|---|---|
| Price | $3.01 | $0.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.67 |
| AVG Volume (30 Days) | 23.0K | ★ 239.0K |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,727,384.00 |
| Revenue This Year | N/A | $355.66 |
| Revenue Next Year | N/A | $849.08 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 40.04 |
| 52 Week Low | $2.85 | $0.13 |
| 52 Week High | $9.67 | $3.26 |
| Indicator | CFND | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 36.47 | 23.93 |
| Support Level | $2.85 | $0.19 |
| Resistance Level | $3.53 | $1.55 |
| Average True Range (ATR) | 0.10 | 0.10 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 13.13 | 4.84 |
C1 Fund Inc is a non-diversified, closed-end management investment company. The Adviser provides day-to-day investment management services to the Company, which is classified as non-diversified under the Investment Company Act. The Company's investment objective is to maximize its portfolio's total return by principally investing in privately held equity and equity-linked securities of digital asset services and technology companies. Its investments in equity securities include common and preferred shares, securities convertible into common shares, warrants and rights to subscribe to or purchase common shares, and common shares carrying a warrant or right.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.